vibegron - Profile
What are the generic sources for vibegron and what is the scope of patent protection?
Vibegron
is the generic ingredient in one branded drug marketed by Sumitomo Pharma Am and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Summary for vibegron
| International Patents: | 122 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vibegron
Generic Entry Date for vibegron*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for vibegron
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | 12,102,638 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | 8,247,415 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | 12,357,636 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | 8,653,260 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | 12,180,219 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for vibegron
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2018282104 | ⤷ Start Trial | |
| Australia | 2024204591 | ⤷ Start Trial | |
| Brazil | 112019025636 | ⤷ Start Trial | |
| Canada | 3064989 | UTILISATION DE VIBEGRON DANS LE TRAITEMENT DE LA VESSIE HYPERACTIVE (USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER) | ⤷ Start Trial |
| Chile | 2019003533 | Uso de vibegron para tratar vejiga sobreactiva. | ⤷ Start Trial |
| China | 110869022 | 使用维贝隆以治疗膀胱过度活动症 (USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER) | ⤷ Start Trial |
| China | 117695286 | 使用维贝隆以治疗膀胱过度活动症 (Use of viberon to treat overactive bladder) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for vibegron
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2276756 | 49/2024 | Austria | ⤷ Start Trial | PRODUCT NAME: VIBEGRON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/24/1822 (MITTEILUNG) 20240628 |
| 2276756 | LUC00366 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/24/1822 20240628 |
| 2276756 | 24C1051 | France | ⤷ Start Trial | PRODUCT NAME: VIBEGRON OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/24/1822 20240628 |
| 2276756 | 2024C/551 | Belgium | ⤷ Start Trial | PRODUCT NAME: VIBEGRON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/24/1822 20240628 |
| 2276756 | CA 2024 00054 | Denmark | ⤷ Start Trial | PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1822 20240628 |
| 2276756 | C20240046 | Finland | ⤷ Start Trial | |
| 2276756 | C202430058 | Spain | ⤷ Start Trial | PRODUCT NAME: VIBEGRON O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/24/1822; DATE OF AUTHORISATION: 20240627; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1822; DATE OF FIRST AUTHORISATION IN EEA: 20240627 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Investment Scenario, Market Dynamics, and Financial Trajectory for Vibegron
More… ↓
